The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX).
Ursula Pluschnig
Disclosure not yet available
Johannes Zacherl
Disclosure not yet available
Sebastian Schoppmann
Disclosure not yet available
Markus Raderer
Disclosure not yet available
Gerhard Prager
Disclosure not yet available
Rupert Bartsch
Disclosure not yet available
Ahmed Ba-Ssalamah
Disclosure not yet available
Wolfgang Lamm
Disclosure not yet available
Christoph Zielinski
Disclosure not yet available
Michael Hejna
Disclosure not yet available